Drug information provided by: Merative, Micromedex®
Pemetrexed injection is used in combination with pembrolizumab and platinum cancer medicines as the first treatment of metastatic (cancer that has spread) non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK gene mutations. It is also used together with cisplatin as the first treatment of advanced or metastatic, non-squamous NSCLC.
Pemetrexed injection is also used as maintenance treatment of advanced or metastatic NSCLC that has not progressed after a previous 4-cycle treatment with platinum cancer medicines. It is also used to treat metastatic non-squamous NSCLC that has come back after a previous chemotherapy.
Pemetrexed injection is also used together with cisplatin as the first treatment of malignant pleural mesothelioma (cancer that affects the inside lining of the lungs and chest wall) that cannot be removed by surgery. Pemetrexed belongs to the group of medicines called antineoplastics.
This medicine is given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: May 01, 2023
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
A generous benefactor has pledged $1 million and challenged us to raise an additional $250,000. Help us reach our goal!